The Long Run with Luke Timmerman podcast

Ep191: Emily Conley on Small Molecules to Correct a Rare Kidney Disease

0:00
1:07:34
Reculer de 15 secondes
Avancer de 15 secondes
Emily Conley, CEO of Berkeley, CA-based Renasant Bio, on developing small molecule correctors and potentiators for autosomal dominant polycystic kidney disease (ADPKD).

D'autres épisodes de "The Long Run with Luke Timmerman"